Geode Capital Management
IKT icon

Geode Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Geode Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.65M Buy
2,170,186
+1,041,947
+92% +$1.85M ﹤0.01% 2895
2025
Q4 		$2.31M Buy
1,128,239
+15,665
+1% +$24.9K ﹤0.01% 3114
2025
Q3 		$1.8M Buy
1,112,574
+45,874
+4% +$79.5K ﹤0.01% 3210
2025
Q2 		$2.08M Buy
1,066,700
+741,940
+228% +$1.45M ﹤0.01% 3125
2025
Q1 		$711K Buy
324,760
+1,882
+0.6% +$4.73K ﹤0.01% 3419
2024
Q4 		$1.05M Buy
322,878
+272,813
+545% +$681K ﹤0.01% 3362
2024
Q3 		$65.1K Buy
50,065
+12,735
+34% +$17K ﹤0.01% 4207
2024
Q2 		$48.9K Buy
37,330
+8,638
+30% +$14.9K ﹤0.01% 4287
2024
Q1 		$62K Hold
28,692
– – ﹤0.01% 4274
2023
Q4 		$36.5K Hold
28,692
– – ﹤0.01% 4422
2023
Q3 		$40.5K Buy
28,692
+13,852
+93% +$31K ﹤0.01% 4467
2023
Q2 		$51.6K Sell
14,840
-1
-0% -$4 ﹤0.01% 4500
2023
Q1 		$58.6K Hold
14,841
– – ﹤0.01% 4483
2022
Q4 		$44K Sell
14,841
-30
-0.2% -$119 ﹤0.01% 4627
2022
Q3 		$81K Hold
14,871
– – ﹤0.01% 4642
2022
Q2 		$66K Buy
14,871
+836
+6% +$4.93K ﹤0.01% 4707
2022
Q1 		$124K Buy
14,035
+847
+6% +$6.82K ﹤0.01% 4575
2021
Q4 		$116K Buy
13,188
+8,882
+206% +$98.1K ﹤0.01% 4677
2021
Q3 		$49K Buy
+4,306
New +$58.2K ﹤0.01% 4784

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management's IKT Position: Q1 2026 in Review

Geode Capital Management increased its Inhibikase Therapeutics (IKT) stake by 92% in Q1 2026, buying an estimated $1.85M and bringing the position to 2,170,186 shares worth $3.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2895.

Geode Capital Management first reported a position in IKT in Q3 2021 and has held it in 19 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Geode Capital Management held 2,170,186 shares of Inhibikase Therapeutics worth $3.65M as of Q1 2026.
  • Geode Capital Management bought 1,041,947 Inhibikase Therapeutics shares in Q1 2026, an estimated $1.85M.
  • Inhibikase Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2895 holding.
  • Geode Capital Management first reported a position in Inhibikase Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.